Market Overview

Earnings Preview for Mersana Therapeutics


Mersana Therapeutics (NASDAQ: MRSN) releases its next round of earnings this Friday, August 07. Here's Benzinga's essential guide to Mersana Therapeutics's Q2 earnings report.

Earnings and Revenue

Based on management's projections, Mersana Therapeutics analysts modeled for EPS at $-0.3 per share on sales of $300.00 thousand. In the same quarter last year, Mersana Therapeutics reported EPS of $-0.36 on sales of $202.00 thousand. The analyst consensus estimate would represent a 16.67% increase in the company's earnings. Mersana Therapeutics's reported EPS has stacked up against analyst estimates in the past like this:

Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019
EPS Estimate -0.37 -0.38 -0.37 -0.38
EPS Actual -0.35 -0.34 -0.35 -0.36
Revenue Estimate 390.00 K 290.00 K 290.00 K 740.00 K
Revenue Actual 11.00 K 42.00 K 844.00 K 202.00 K

Stock Performance

Over the last 52-week period, shares are up 555.95%. Given that these returns are positive, long-term shareholders can be satisfied going into this earnings release.

Looking at these results, shareholders should be feeling unsatisfied with these results.

Don't be surprised to see the stock move on comments made during its conference call. Mersana Therapeutics is scheduled to hold the call at 08:00:00 ET and can be accessed here:


Related Articles (MRSN)

View Comments and Join the Discussion!

Posted-In: Earnings